Figure 1. Rebound Phenomenon of Platelet Reactivity After Stopping Long-Term Clopidogrel Therapy (A) Study flow. (B) Increase in P2Y12 receptor protein expression levels in platelets from baseline to the time of clopidogrel cessation after ≥12 months of therapy. Six patients with P2Y12 levels below the lower detection limit of the standard curve were recorded as zero. (C) Increase in platelet reactivity unit (PRU) levels from baseline to 1 month after the cessation of clopidogrel therapy. (D) The percentages of patients with PRU levels ≥208 (left) or ≥252.5 (right) at baseline and 1 month after the cessation of clopidogrel therapy. The Wilcoxon signed rank test was used for panel B, paired t test for panel C, and chi-square tests for panel D. The red boxes and whiskers represent the median (Q1-Q3) and 1.5× Q1 to Q3 range, respectively, while red dots and error bars represent the mean ± SD. ELISA = enzyme-linked immunosorbent assay.
Answers are grounded in this paper and cite their sources.
Clinicians should exercise caution stopping long-term clopidogrel; hypothesis-generating for randomized trials of discontinuation safety.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: